Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Outcomes of complement inhibition with eculizumab in adult TA-TMA

Eleni Gavriilaki • 2 Feb 2021
TCT 2021
Eculizumab

Eleni Gavriilaki, MD, PhD, George Papanicolaou Hospital, Thessaloniki, Greece, discusses the results of an analysis aiming to compare strategies and outcomes of patients with transplant-associated thrombotic microangiopathy (TA-TMA) treated with eculizumab. At a median follow-up of 11.1 months, overall survival was found to be significantly higher in patients that received eculizumab, suggesting benefit for complement inhibition in this patient population. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Eleni Gavriilaki

The current approach to response assessment in TA-TMA
1:36
The current approach to response assessment in TA-TMA
Eleni Gavriilaki • 25 Mar 2026
The current approach to severity scoring in TA-TMA
1:21
The current approach to severity scoring in TA-TMA
Eleni Gavriilaki • 25 Mar 2026
Moving the field forward in TA-TMA: insights from an educational session
2:26
Moving the field forward in TA-TMA: insights from an educational session
Eleni Gavriilaki • 25 Mar 2026
Endothelial injury syndromes in hematology: unifying the terminology
1:44
Endothelial injury syndromes in hematology: unifying the terminology
Eleni Gavriilaki • 13 Jun 2025

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals